Pharmacology High Yields Flashcards
Azathioprine, 6-MP, G-TG
Mechanism: purine analog; activated by HGPRT; AZ –> 6-MP
Use: preventing organ rejection, RA, IBD, SLE, ALL
Toxicity: Myelosuppression, GI, liver (Jaundice)
AZ and 6-MP are metabolized by xanthine oxidase (and TPMT in liver), thus both have increased toxicity with allopurinol or febuxostat
Works during S phase
Cladribine (2-CDA)
Mechanism: purine analog; resistant to degradation by adenosine deaminase
Use: Hairy cell leukemia
Toxicity: myelosuppression, nephrotoxicity and neurotoxicity
Cytarabine (arabinofuranosyl cytidine)
Mechanism: pyrimidine analog –> inhibition of DNA polymerase
Uses: AML, lymphomas
Toxicity: leukopenia, thrombocytopenia, megaloblastic anemia
“CYTarabine causes panCYTopenia”
5-FU
Mechanism: pyrimidine analogue, bioactivated to 5F-dUMP, which covalently complexed with folic acid and inhibits thymidylate synthase -> decreased DNA synthesis
Uses: colon cancer, pancreatic cancer, basal cell carcinoma
Toxicity: mylosuppression NOT reversed by leucovorin (folinic acid)
MTX
Mechanism: Folic acid analog that competitively inhibits dihydrofolate reductase –> decreased DNA synthesis
Uses: ALL, lymphoma, ectopic pregnancy, medical abortion, RA, psoriasis, IBD, vasculitis
Toxicity: myelosuppression which IS reversible with leucovorin “rescue” ; hepatoxocity, mucositis (mouth ulcers), pulmonary fibrosis, teratogen, nephrotoxicity
Bleomycin
Mechanism: Induces free radical formation –> breaks in DNA strands
Use: testicular cancer, Hodgkin lymphoma
Toxicity: pulmonary fibrosis, skin hyperpigmentation, mucositis, minimal myelosuppression
Acts during G2 phase
Dactinomycin
Mechanism: intercalates in DNA –> inhibition of DNA-dep. RNA pol.
Use: Wilms tumor, Ewing sarcoma, rhabdomyosarcoma - tumors of childhood (“children ACT out”)
Toxicity: myelosuppression, radiation recall
Doxorubicin/Daunorubicin
Mechanism: generate free radicals; intercalate in DNA –> breaks in DNA
Use: solid tumors, leukemia, lymphoma
Toxicity: dilated cardiomyopathy, myelosuppression, alopecia
Dexrazoxane
Iron chelating agent used to prevent cardio toxicity from doxorubicin and daunorubicin
Leucovorin
Folinic acid - N5-formyl-THF; used to overcome myelosuppression in Methotrexate usage NOT 5-FU usage
Busulfan
Mechanism: cross-links DNA
Use: CML, bone marrow ablation
Toxicity: myelosuppression severe, pulmonary fibrosis, hyperpigmentation, seizures
Cyclophosphamide/Ifosfamide
Mechanism: Cross-link DNA at guanine N-7; requires bioactivation by P450 in liver
Use: Solid tumors, leukemia, lymphoma, immunosuppression
Toxicity: hemorrhagic cystitis (partially prevented with MESNA)
MESNA
thiol group of mesna binds toxic metabolites and helps to reduce hemorrhagic cystitis when using cyclophosphamide
Nitrosoureas
Carmustine, Lomustine, Semustine, Streptozocin
Mechanism: requires bioactivation; cross blood brain barrier (lipid soluble); cross link DNA; effective in CNS
Use: brain tumors
Toxicity: CNS - convulsions, dizziness, ataxia, nephrotoxicity
Paclitaxel/Taxols
Mechanism: hyperstabilize polymerized microtubules in M phase so that mitotic spindle cannot break down and anaphase cannot occur
Use: Ovarian and breast cancer; coat stents
Toxicity: myelosuppression, alopecia, hypersensitivity
Vincristine/Vinblastine
Mechanism: vinca alkaloids that bind beta-tubulin and inhibit polymerazation into microtubules –> prevent mitotic spindle formation (M phase)
Use: solid tumors - testicular breast - NSCLC - Hodgkin (vinblastine) and non-Hodgkin (vincristine), ALL
Toxicity: Neurotoxicity - peripheral neuritis (Vincristine), paralytic ileus (Vincristine), Marros suppression (Vinblastin - Blasts bone)
Cisplatin/Carboplatin
Mechanism: cross-link DNA
Use: testicular, bladder, ovary and lung carcinoma
Toxicity: nephrotoxicity (prevent with amifostine and chloride diuresis), ototoxicity
Amifostine
Free radical scavenger used to treat cisplatin nephrotoxicity
Etoposide/Teniposide
Mechanism: inhibit topoisomerase II –> DNA degradation
*S–>G2 phase
Use: solid tumors - testicular and SCLC - leukemia, lymphoma
Toxicity: myelosuppression, GI upset alopecia
Irinotecan/Topotecan
Mechanism: inhibit topoisomerase I and prevent DNA unwinding and replication
*S –> G2 phase
Use: colon cancer, ovarian and SCLC
Toxicity: myelosuppression, diarrhea
Hydroxyurea
Mechanism: inhibit ribonucleotide reductase –> decreased DNA synthesis (S phase specific)
Use: melanoma, CML, sickle cell (increases HbF)
Toxicity: severe myelosuppression, GI upset
Bevacizumab
Mechanism: monoclonal antibody against VEGF –> inhibit angiogenesis
Use: solid tumors - colorectal and renal cell
Toxicity: hemorrhage, blood clots, impaired wound healing
Erlotinib
Mechanism: EGFR tyrosine kinase inhibitor
Use: NSCLC
Toxicity: rash
Imatinib
Mechanism: tyrosine kinase inhibitor of BCR-ABL and c-kit
Use: CML, GI stromal tumors
Toxicity: fluid retention, heart failure
Rituximab
Mechanism: monoclonal antibody against CD20, found on most B cell neoplasms
Use: Non-Hodgkins, CLL, IBD, RA
Toxicity: increased risk of progressive multifocal leukoencephalopathy, infusion rxn, tumor lysis sydrome
Tamoxifen/ Raloxifene
Mechanism: selective estrogen receptor modulator (SERM) - block the bind of estrogen to ER+ cells
Use: breast cancer (Tamoxifen) Osteoporosis prevention (Raloxifen)
Toxicity: increased risk of endometrial cancer; hot flashes (tamoxifen)
Trastuzumab (Herceptin)
Mechanism: monoclonal antibody against HER-2 (c-erbB2) - a tyrosine kinase inhibitor; through inhibition of HER-2-initiated cellular signaling and antibody-dependent cytotoxicity
Use: Her2+ breast canse and gastric cancer
Toxicity: cardiotoxicity - “HEARTceptin”
Vemurafenib
Mechanism: small molecule inhibitor of BRAF oncogene + melanoma
Use: metastatic melanoma
Vemurafenib
Mechanism: small molecule inhibitor of BRAF oncogene + melanoma
Use: metastatic melanoma
Alpha 1
Gq
Gq
PLC –> DAG/IPS –> Ca2+/Calmodulin/PKC –> Phosphorylation
Gs
ATP–> cAMP –> PKA
Alpha 2
Gi
Beta1 & Beta2
Gs
M1 & M3
Gq
M2
Gi
D1
Gs
D2
Gi
H1
Gq
H2
Gs
V1
Gq
V2
Gs
Bethanechol
Muscarinic agonist; Tx of Ileus and urinary retention (resistant to esterase)
Carbachol
Muscarinic/nicotinic agonist; Causes contraction of ciliary muscle for open-angle glaucoma; constricts pupil
Pilocarpine
Muscarinic agonist; stimulates tears, sweat and saliva; Constricts pupil and ciliary muscle - acute glaucoma tx.
Clonidine
Agonist of central alpha2 adrenergic receptors –> decreased sympathetic outflow
Nonselective Alpha Blockers
Phenoxybenzamine (irreversible)
Phentolamine (reversible)
Alpha 1 Selective Blockers
Prazosin, Terazosin, Doxazosin (longest acting)
Tx. of HTN and BPH; may cause orthostatic hypotension so take at bedtime
Alpha 2 Selective Blockers
Mirtazapine - treatment of depression; can cause sedation, increased cholesterol and increased appetite
Alpha 2 Selective Blockers
Mirtazapine - treatment of depression; can cause sedation, increased cholesterol and increased appetite
Mixed Alpha and Beta Blockers
Carvedilol
Labetalol
Partial Beta Agonists
Pindolol
Acebutolol